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Avoiding mechanical ventilation of preterm infants is important to prevent morbidity and 
mortality. Non-invasive ventilation and CPAP has been shown to be superior to intubation 
and mechanical ventilation in preventing chronic lung disease in very preterm infants.1 . 
CPAP for infants was first used in the early 70’s. Since then, several different CPAP devices 
have been developed. Some of them are designed to give long term respiratory support while 
others are designed for initial support, with the possibility to give positive pressure ventilation 
(PPV) if needed. Some are expensive and complicated with several add on features while 
other are cheap, with simple mechanisms and easy to use.  
The goal for CPAP treatment is to give continuous airway pressure to the infants in order to 
minimize the work of breathing and improve gas exchange. But are all CPAP systems the 
same? Do all CPAP systems deliver stable airway pressure which helps the infants with their 
work of breathing?  
The overall aim of this thesis was to evaluate existing and newly developed devices for non-
invasive respiratory support used in neonates in the DR and the NICU. The focus was on 
device resistance, pressure stability, imposed work of breathing and interfaces used. 
The aim of Paper I was to examine the in vitro performance of a new system (rPAP) and to 
perform a clinical feasibility trial, comparing a T-piece system with face mask, and the new 
system with face mask or nasal prongs, for initial stabilization of preterm infants. The new 
device was shown in a mechanical lung model to be pressure stable and have low imposed 
work of breathing compared to the T-piece. The feasibility trial comparing these devices 
revealed no safety issues when stabilizing preterm infants with the new device. 
The aim of Paper II was to examine the in vitro performance of the Medijet CPAP reusable 
and disposable generators and compare them to other CPAP systems. The main mechanism 
of CPAP generation for the disposable Medijet generator was shown to be resistance. The 
Medijet systems shows increasing resistance to breathing with each design generation. Our 
results suggest that the disposable Medijet should be used cautiously in patients where low-
resistance and pressure-stable CPAP is believed to be clinically important. 
The aim of Paper III was to compare the revised Pumani CPAP system with two traditional 
bubble CPAP systems, focusing on in-vitro performance and safety. The revised Pumani 
system had high resistance, high imposed work of breathing and submersion depth had 
almost no impact on the delivered pressure which is the main CPAP generating mechanism 
of true bubble CPAP systems.  
The aim of Paper IV was to evaluate if using the new system (rPAP) with nasal prongs as 
interface, could reduce the need for intubation of extremely preterm infants in the DR 
compared to using the standard T-piece system with face mask. The CORSAD randomized 
controlled trial showed that using the new system decreased delivery room intubations in 
extremely preterm infants and creates thereby a possibility to avoid mechanical ventilation. 
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Being born, taking the first breath and continue breathing is challenging, especially if a baby 
is born prematurely. Providing adequate respiratory support is essential and potentially 
lifesaving. Continuous positive airway pressure or CPAP is the most common respiratory 
support given to a new-born infant. CPAP applies a continuous distending pressure to 
spontaneously breathing infants by means of an interface, to facilitate lung expansion and 
make breathing easier.  
Non-invasive ventilation and CPAP has been shown to be superior to intubation and 
mechanical ventilation in preventing chronic lung disease in very preterm-born infants.1 
Different strategies and different devices have been developed, all aiming to improve the 
non-invasive approach and to avoid mechanical ventilation. Since Gregory’s first infant 
CPAP device2, several different CPAP devices have been developed. Some of them are 
designed to give initial support, with possibilities to give positive pressure ventilation (PPV) 
if needed. Other are designed to give long term respiratory support in the neonatal intensive 
care unit (NICU). Some are cheap, developed for low-income countries, whilst others are 
complicated and expensive, with add on features such as bi-level pressures and high 
frequency oscillating pressures. The ultimate goal for every device is the same: to provide a 
stable, continuous airway pressure to minimize the work of breathing and improve gas 
exchange. But are all CPAP systems the same? Do all CPAP systems deliver stable airway 
pressure which helps the infants with their work of breathing?  
This thesis will focus on CPAP devices that have been developed for neonatal use in the last 
decades. Aspects such as pressure stability, imposed work of breathing (iWOB) and different 





2 LITERATURE REVIEW 
2.1 PHYSIOLOGICAL EFFECTS OF CPAP 
Continuous positive airway pressure is a method for applying a Continuous Distending 
Pressure (CDP) to spontaneously breathing patients during inspiration and expiration.3 CDP 
increases transpulmonary pressure, which in newborn infants helps to establish and maintain 
Functional Residual Capacity (FRC) and facilitate gas exchange.4-6 CPAP splints the upper 
airway , decreases the upper airway resistance and reduces the risk for obstructive apnea.7,8 
With improved oxygenation and a stable FRC, CPAP may also reduce the risk of severe 
central apnea.9-11 CPAP lowers work of breathing, decreases thoraco-abdominal asynchrony, 
and conserves surfactant and facilitates its function.12,13 The CDP is also the driving force 
required to overcome elastic, flow-resistive, and inertial resistance of the respiratory system.14 
The most common understanding when referring to CPAP in neonates is that it is non-
invasive with a nasal interface (nCPAP). The major difference in providing CDP non-
invasively (nCPAP) versus invasively (mechanical ventilation) is that the non-invasive 
support is ineffective during apnea. However, as mentioned above, CDP itself can decrease 
the occurrence of apnea and with pleural pressure changes, spontaneous breathing increases 
venous return, improves cardiac output, and improves lung aeration with alveolar recruitment 
and stabilization.15-17 
2.2 THE HISTORY OF CPAP DEVICES 
In 1914, Von Reuss published in a textbook a description of Von-Tiegel’s “over- pressure 
apparatus”.18,19 It consisted of hoses, an oxygen gas source, a tight-fitting face mask, and a 
water-filled receptacle. A metal tube was connected to an expiratory hose that was submerged 
into the receptacle and pressure was controlled by adjusting the tube depth according to a 
centimeter scale.  
More than 50 years later, Gregory et al reported successful CPAP treatment of spontaneously 
breathing preterm infants with RDS.2 The CDP was created with a resistor clamp on the 
expiratory limb of the system. It had a water submersion pop-off pressure valve and has 
therefore often been mistaken for a bubble CPAP (bCPAP) system. Sahni and Wung20 were 
first to describe the original bCPAP system. This design has wide bore expiratory tubing 
submersed in water without a resistor clamp. It had short binasal prongs as interface 
connected directly to the tubing. This made the system more pressure stable than the Gregory 
CPAP and was believed to be easier to breathe through. In 1976, the Benveniste valve was 
introduced as a nasal CPAP device.21 It was originally designed to protect infants from high 
breath volumes and inflation pressures common in the crude ventilators used at the time.22 
The Benveniste valve was the first variable flow system used for nasal CPAP in infants. A 
new variable flow system for infant was introduced by Moa et al in 1988.23 It had short nasal 
prongs as interface and used jets to generate pressure stable CPAP and was later marketed as 
the Infant Flow CPAP. Many other systems have been introduced and built on similar 
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designs. In addition to all these different CPAP systems, modern ventilators are also capable 
of delivering CPAP by a Y-piece and a patient interface. All the above techniques for CPAP 
generation are still in use. Studies comparing CPAP systems are limited and the few 
comparisons that have been undertaken have not shown clear differences between system 
performance. 
2.3 CLASSIFICATION OF CPAP SYSTEMS 
CPAP is derived from either variable or continuous gas flow. In variable-flow CPAP devices, 
pressure is generated proximal to the infant's nares. Turbulence is created to oppose 
expiration and aid inspiration and uses the Venturi effect to redirect the gas flow to create 
constant pressure. In continuous-flow CPAP, the gas flow is directed against a resistance in 
the expiratory limb of the breathing circuit. 
2.3.1 Variable-flow CPAP  
The Infant Flow and the Arabella CPAP system is an example of a device that uses dedicated 
flow drivers and gas generators with a fluidic-flip mechanism (Coanda effect) to create 
variable flow. Pressure stability is achieved by the Venturi effect in combination with the 
fluidic flip, and the patient is connected to the patient with binasal prongs or nasal mask.23,24 
The original Infant Flow system was designed by Gunnar Moa and Kjell Nilsson in the 
1980’s. The flows within the geometry have recently been investigated by computer 
simulations (Figure 1).25 
 
Figure 1: The inventors of the original Infant Flow (Östersund, 1988) and flows within the driving 
geometry investigated using computational fluid dynamics at KTH (Stockholm, 2020). 
 
The Benveniste valve and the original Medijet are examples of alternative variable-flow 
system that also use the Venturi effect to create stable pressure but do not have a fluidic flip 
mechanism. A blended gas source provides a fresh-gas flow that is directed towards an orifice 
which generates variable flow. The device is connected to the patient via nasal prongs.21  
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2.3.2 Continuous-flow CPAP  
Bubble CPAP is a continuous-flow system with wide bore tubing and low-resistance nasal 
prongs. Blended gas is humidified and heated before patient. The expiratory tubing is 
submersed distally in a water bottle and the depth of submersion reflects the delivered CPAP 
pressure in centimetres.20 
Another example of continuous flow CPAP is ventilator-derived CPAP. By varying the 
ventilator's expiratory orifice size CPAP is increased or decreased. Pressure, flow and the 
exhalation valve works in synchrony to maintain the desired CPAP level. A summary of 
different CPAP generation is shown in Table1. 
 
Mechanism History Flow Mechanism Stable CPAP? 
Resistor Gregory’s CPAP 
T-Piece 
resuscitator 
Constant and not 
used to adjust 
CPAP 
Resistance on 
expiratory limb or 
device to adjust 
CPAP 
Depending on 
level of fresh 
gas flow 
Bubble Used by Wung, 
Columbia, USA 
Constant and not 













Variable, used to 
adjust CPAP level  
Turbulent flow 
opposing exhalation 
















Table 1: Principles for CPAP generation. Some CPAP systems display features of several 
mechanism e.g. the Medijet is both a resistor and flow opposition system and the Pumani is 




2.4 PATIENT INTERFACES 
There are several interfaces in use to deliver nCPAP in infants (Figure 2). These include 
single and binasal prongs, short and long versions and also nasal masks. Hudson, Argyle and 
Infant flow are examples of short nasal prongs, and nasopharyngeal tubes and Duotube are 
examples of long nasal prongs. Older CPAP interfaces such as endotracheal tubes, head 
boxes, face chambers, and full-face masks are no longer in use in modern day NICU’s. Nasal 
cannulas are sometimes used as CPAP interfaces but they are not marketed or tested for 
CPAP use and should therefore not be used as such. 
 
 
Figure 2: A variety of nasal CPAP interfaces. 
In recent years, evidence has shown that short nasal prongs and nasal mask seem to be 
superior to long nasal prongs. De Paoli et al. compared, in vitro, different interfaces for 
nCPAP treatment in neonates. Short binasal prongs had the lowest resistance to flow, and the 
authors concluded that large pressure variations could occur in clinical settings.12 In a clinical 
study by Davis et al., using short binasal Hudson prongs lead to significantly lower incidence 
of respiratory failure within seven days post extubation compared with using a single long 
prong.26 Roukema et al. compared short binasal prongs with nasopharyngeal prongs and 
reported a lower rate of reintubation for short prongs.27 A Cochrane review concluded that 
short binasal prongs are more effective than single prongs in reducing the rate of reintubation 
in preterm neonates.28 A trial comparing nasal prongs and nasal masks for delivering CPAP 
to preterm infants <31 weeks of gestational age showed that the nasal mask was more 
effective than nasal prongs for preventing intubation within 72 h of starting therapy.29 Green 
et al compared, in vitro settings, different brands of short nasal prongs, masks and even 
included the RAM cannula. They concluded that use of interfaces with high resistance results 
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in a greater drop in delivered airway pressure in comparison to set circuit pressure and this 
could have impacted clinical efficacy.30  
The 2019 European RDS guidelines recommend using short binasal prongs or nasal mask 
when commencing CPAP treatment for preterm infants.31 
 
2.5 PRESSURE STABILITY AND IMPOSED WORK OF BREATHING OF CPAP 
DEVICES  
When breathing through a device, the airway pressure will fluctuate during the breathing 
cycle. Inspiration will lead to a decreased airway pressure and expiration will lead to an 
increased airway pressure. It is the patient that generates theses pressure changes and they 
represent the extra work needed to breathe through a device. This extra work is called 
imposed work of breathing (iWOB). For CPAP systems that are pressure-unstable, the 
fluctuations will be large and the iWOB will be high. Investigate pressure stability can be 
done in a number of ways but they all reflect the relation between pressure and flow for a 
device (Figure 3).  
Pressure can be measured at a given time, flow or volume, for example during one breath. 
Imposed work of breathing is an integration of pressure over volume for one breath. It can be 
divided into an expiratory and inspiratory part. Every breath has a pressure-volume loop in 
the same way as we see on the screen of ventilators, and the work of breathing can be 
calculated from the area within a single breath. Imposed work of breathing can be averaged 
over time or per volume.32 
 
 
Figure 3: Illustration of pressure stability during spontaneous breathing. High amplitude of the 
pressure fluctuations during breathing (up/down) corresponds to a wider pressure-volume loop 
(left/right) and a larger iWOB. The illustration in black has a higher resistance to breathing, with 
















2.6 METHODS USED TO MEASURE PRESSURE STABILITY AND IWOB 
2.6.1 Static tests 
A simple way to describe resistance is the pressure changes at a given flow. This simple static 
model makes experiments easy to perform and understand, without the need to accurately 
reproduce flow profiles or volumes. 
2.6.2 Dynamic tests 
Mechanical lung simulators are needed for dynamic tests. These can simulate spontaneous 
breathing, allowing us to compare the pressure stability of different devices and variables. 
Simulations can be either non-compliant (volume or flow pump) or complex (including 
compliance and resistance). 
2.6.3 In vitro comparison of CPAP devices 
Moa et al compared a new system (Infant Flow) to a continuous flow CPAP system and 
showed that the new system was more pressure stable and less sensitive to leakage.24 
Klausner et al used a mechanical lung model to compare a variable flow system (Arabella) to 
a continuous flow system and showed lower iWOB for the Arabella system.33 Drevhammar 
et al compared seven CPAP systems.34 They showed large variations in iWOB and pressure 
stability with AirLife and Infant flow having the lowest iWOB while NeoPuff and Medijet 
had the highest. 
2.7 CPAP DEVICES IN LOW RESOURCE SETTINGS 
Providing respiratory support for infants in low-income settings is challenging. Access to 
inexpensive CPAP respiratory support is highly prioritized by the World health organization ( 
WHO), which in a 2012 statement highlighted this as an area in need of innovation and 
implementation.35 Bubble CPAP has major advantages compared to CPAP provided by more 
expensive devices such as existing variable flow systems or modern ventilators. The 
combination of low price, simple technique, well-proven clinical effect, and no need for 
pressure monitoring makes bubble CPAP ideal for use in lower-middle countries. In the last 
decade, new devices have been designed for use in low resource settings. Almost all are 
based on the original bubble CPAP design, often with modifications. The development of 
new systems has not been without concerns. The WHO stated: ‘Increasing use of CPAP 
without regulation is a concern. Many devices are in the “homemade” category; several low-
cost bubble CPAP devices are being developed specifically for low-income countries but 
need to be tested for durability, reliability and safety’.36 It is of great importance to conduct 
quality research on the effectiveness, sustainability and safe implementation of bCPAP 
design alterations for use in low resource settings. 
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2.8 RESPIRATORY SUPPORT DEVICES FOR DELIVERY ROOM 
MANAGEMENT 
The delivery room management of the preterm infant is moving towards a less invasive 
approch.37 The benefit of non-invasive management was first noted in observational 
studies38,39 and then in a randomized trials , such as the COIN, CURPAP, VON and 
SUPPORT trials.40-43 A Cochrane review from 2016 concludes that prophylactic nasal CPAP 
in very preterm infants reduces the incidence of BPD or BPD and death, compared to 
intubation and mechanical ventilation.1 The European guidelines for the treatment of RDS 
2019 and The International Liaison Committee on Resuscitation (ILCOR) consensus 
document 2020, recommend using CPAP rather than intubation and mechanical ventilation 
for initial stabilization of spontaneous breathing preterm infants with respiratory distress.31,44 
To establish stable spontaneous breathing in a newborn preterm infant, positive pressure 
ventilation (PPV) is often needed. The techniques available for non-invasive PPV are T-piece 
resuscitators, self-inflating bags or flow-inflating bag systems.45 All are used with a facemask 
as patient interface. The T-piece systems can be used to provide CPAP and bag systems can 
have a built-in positive end expiratory pressure (PEEP) valve. For some of these bag and 
PEEP valve systems, this design is quite ineffective and PPV needs to be delivered at a high 
rate in order to create PEEP and CPAP cannot be generated during spontaneous breathing.45-
47 Animal studies have shown convincingly that PEEP is beneficial in creating FRC48, 
however clinical studies have failed to show marked clinical significance with the devices 
used today.44 Animal studies have also shown that when preterm rabbits are apnoeic the 
larynx is closed which makes both PEEP and PPV ineffective.49 PPV even triggered closure 
of the larynx in rabbit pups who already had a stable breathing pattern. The authors 
concluded that very preterm infants could benefit from focusing on spontaneous breathing 
rather than providing PPV with face mask. It is known that stimulation of the trigeminal 
nerve in infants, can cause a cessation of breathing pattern, bradycardia, peripheral 
vasoconstriction and closure of the larynx.50,51 In 2018, Martherus et al52 speculated in a 
review, that using a facemask as an interface could influence the breathing pattern of infants 
via the trigeminal nerve. Apnea after the placement of facemask in newborn infants was later 
confirmed by Kuypers et al in a retrospective study reviewing resuscitation video recording.53 
A new system, the rPAP, was recently introduced. It is a variable flow device and has a 
marked reduction in imposed work of breathing (iWOB) compared to the traditional T-
piece.54 The system is handled in a similar way as the standard care T-piece system, delivers 
of PPV by occlusion at an aperture on the device, and can be used with nasal prongs/mask as 
the patient interface.  
The combination of various devices and interfaces for CPAP support complicates the process 
of deciding which systems are best suited for neonatal use. The ILCOR guidelines highlight 
this problem: "Interpretation of human studies is further complicated by varying interfaces 
(e.g., face mask versus endotracheal tube) and methods of generating PEEP (e.g., self-
inflating bags with PEEP valve versus T-piece resuscitator)".55 The clinical effect of using 
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different interfaces and devices, and the impact of the CPAP level given in the delivery room 
has been insufficiently studied and high quality randomized controlled trials in preterm 




3 RESEARCH AIMS 
The general aim of this thesis was to evaluate existing and newly developed devices for non-
invasive respiratory support used in neonates in the DR and the NICU. The focus was on 
device resistance, pressure stability, imposed work of breathing and interfaces used. 
 
Specific aims: 
I. To describe the performance of a new system(rPAP) “in vitro”, then to perform a 
clinical feasibility trial comparing a T-piece system with face mask, and the new 
system with face mask or nasal prongs, for initial stabilization of preterm infants. 
 
II. To describe the “in vitro” performance of the Medijet CPAP reusable and 
disposable generators and compare this to the Neopuff resistor system and two 
non-resistor systems (the Infant Flow and Benveniste valve). 
 
III. To compare the Pumani system with two traditional bubble CPAP systems, 
focusing on “in-vitro” performance and safety. 
 
IV. To evaluate if a new system, with low iWOB and nasal prongs as interface, could 
reduce the need for intubation of extremely preterm infants in the DR compared to 





4 MATERIALS AND METHODS 
The studies that this thesis is based on include both preclinical in vitro experiments as well as 
clinical trials. Device testing was performed in our lab at Östersund Hospital, Sweden and 
clinical trials at the Karolinska University Hospital in Stockholm, Sweden and (in paper IV) 
six other centers in Europe. 
 
4.1 THE NEW RESUSCITATION SYSTEM 
The new resuscitation system, now called rPAP, was designed in a collaboration with our 
research group. The original prototype was designed by Kjell Nilsson and Thomas 
Drevhammar. The author of this thesis, among others, gave clinical feedback on the design 
and function. Minor design alterations were made before the device was CE certified. The 
new system is driven by two flows, one jet flow and one bias flow. The jet flow creates the 
CPAP and the addition of the bias flow enhances the inspiratory rise time during PPV. The 
system can be used with either face mask or nasal interface.  
 
4.2 IN VITRO EXPERIMENTS (PAPER I, II AND III) 
The “in vitro” experiments were performed with either dynamic tests (paper I-III) or static 
tests (paper II and III).  
4.2.1 Dynamic tests 
A mechanical lung model (ASL 5000, IngMar Medical, Pittsburg, Pennsylvania, USA) was 
used in dynamic experiments and to simulate breathing for all test systems. To simulate 
breathing, a simple noncompliant flow pump mode was used. We used a fixed volume 
syringe and a calibrated pressure transducer (VT PLUS HF, Fluke Biomedical, Everett, 
Washington, USA) to standardize the accuracy of volumes and pressures. Sinusoidal flow 
profiles with respiratory rate of 60 per minute and an inspiratory-to-expiratory time ratio of 
1:1 were used. A tidal volume of 32 mL were used in all in vitro experiments. In addition, 16 
mL tidal volume was also investigated in paper I. All systems were tested at different CPAP 
levels and with non-humidified air at room temperature. iWOB was calculated for each 
breath from the area within the pressure volume loop (modified ASL V.3.1 software). This 
method has been described in detail by Banner32 and Drevhammar34. 
4.2.2 Static tests 
The static experiments performed in paper II and III examined pressure changes due to 
resistance both with and without simulated airway flow. In paper II the effect of directing 
flow through the driver port with the patient interface closed was compared to doing the 
opposite, that is delivering fresh gas flow through the patient interface with the driver port 
occluded. This was done to investigate whether the Medijet generator created CPAP due to 
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variable flow (Coanda effect) or simply due to resistance. The pressure stability of the 
devices was investigated at 5 cm H2O of CPAP with simulated airway flow from -10 L/min 
to + 10 L/min, with negative flow representing inspiration and positive flow representing 
expiration. In both paper II and III devices were compared with regards to pressure changes 
when increasing the fresh gas flow, gradually from 0-10 L/min through the driver port with 
the patient interface closed, at a set CPAP level or submersion depth. In paper III the effect of 
the submersion depth was investigated for different devices. In addition, the resistance of 
tubing of the Pumani system was tested by gradually dissembling the connections at 6 
different points.  
4.2.3 Statistical analysis 
Statistical analyses were performed using ANOVA with Bonferroni correction and mean data 
was presented with standard deviation (supplementary tables) or 95% confidence 
interval(figures). P < 0.05 was considered to be statistically significant. 
 
4.3 CLINICAL FEASIBILITY TRIAL (PAPER I) 
The clinical feasibility trial comparing the newly developed system to standard T-piece 
system started in 2012. From 2012 to 2015, 36 infants with gestational age between 27w-
34w, were recruited. Informed consent was obtained from mothers with threating preterm 
labour and the infants were randomized into 3 groups. The groups were new system with 
prongs, new system with face mask and standard T-piece system with face mask. The trial 
was a feasibility trial and therefore not designed to estimate treatment effects and no power 
calculations were performed. The intervention was CPAP for at least 10 min after birth and 
PPV if needed. The intervention ended with either establishment of stable spontaneous 
breathing or intubation. Outcomes included respiratory and safety parameters and the follow 
up period was 72 hours after birth.  
4.3.1 Statistical analysis 
Normal distribution was tested with Shapiro-Wilk test. Normal distributed data was presented 
as mean (SD) and differences were tested with ANOVA. Non-normal distributed data was 
presented as median with inter quartile range and differences was tested with Kruskall-Wallis 
test. Nominal data were tested with Fisher’s exact test. p < 0.05 was considered statistically 
significant. 
 
4.4 THE CORSAD TRIAL (PAPER IV) 
The CORSAD (Comparison Of Respiratory Support After Delivery on infants born before 28 
weeks gestational age) Trial was a two armed, nonblinded, randomized trial in seven centers 
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in five countries. The study had local ethical consent in each of the five countries. It was 
funded by unrestricted academic research grants and no corporate funding was allowed. 
The trial was performed according to Good Clinical Practice (GCP) following the principles 
of the Declaration of Helsinki56 and registered at clinicaltrials.gov before the start of the trial. 
Before each study site initiation, on site DR training was performed and web-based training 
module introduced. Infants were recruited after screening and informed consent of mothers 
with threatening preterm labor before 28 w GA in absence of prespecified exclusion criteria. 
Informed consent was prospective in all cases. Randomization was stratified on center, 
antenatal steroid treatment and GA. Patients were randomized with a computer genericide 
randomization system shortly before birth in a 1:1 ratio to either the new system group with 
nasal prongs or the standard T-piece system with facemask. The same system was used for 
multiple births infants. 
The delivery room intervention was CPAP for the first 10-30 minutes after birth and PPV as 
needed. Intervention ended when the infant had established stable breathing on CPAP or was 
intubated. CPAP pressures allowed were 5-8 cm H2O and PIP pressures 20-25 cm H2O. 
Routine DR care for thermal regulations, oxygenation, monitoring and post intervention care 
followed International Guidelines31,44 and local protocols. 
The primary outcome was intubation or death in DR within the time frame of 0-30 minutes. 
The intubation criteria included persistent bradycardia, apnea, poor respiratory effort and 
inadequate oxygenation. Secondary outcomes included respiratory and safety variables. 
The trial was conducted according to GCP to increase data quality but this was not required 
since both systems were CE-labelled. An independent Data Monitoring Committee (DMC) 
reviewed data on safety, progress and study conduct on a regular bases during the trial period. 
All adverse event and deaths were reviewed by the DMC. 
4.4.1 Statistical analysis 
We calculated the number of patients needed from a baseline intubation rate of 60% in 
extremely preterm infants born in Sweden prior to the trial.16 Estimated treatment effect was 
not known,so an 20% absolute reduction was judged to be clinically important. The 
calculated number of infants was 195 with a binary outcome superiority trial design at 
significance level (alpha) of 5% and power (1-beta) of 80%. This was increased to 250 
patients to accommodate stillborn, protocol violations, baseline intubation rate changes, and 
center differences. The primary outcome was analyzed using a logistic regression model 
adjusted for stratification variables. The model was also used for estimating an adjusted risk 
difference. A multivariate GEE logistic regression model, adjusting for multiple births was 
also performed. Binary outcomes and demographic variables were compared by chi-square or 
Fisher’s exact test as appropriate. Continuous data were compared using t-tests or non-
parametric test after tests of normality. Risk ratios and risk difference for secondary outcomes 
with 95% CI were calculated using cross tabulation risk function or in Excel version 16 
(Microsoft, Redmond, WA, USA). Kaplan Meier method was used for cumulative incidences 
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of DR primary outcome followed by NICU mechanical ventilation or death up to 72 h. All 
analyses were two-sided, based on intention-to-treat and p<0.05 considered statistically 
significant. No adjustments for multiple comparisons were made and secondary outcome 





5.1 PAPER I 
The in-vitro simulations showed that the new system had better pressure stability and a 
marked reduction in iWOB compared to standard T-piece systems represented by GE and 
Neopuff. With a tidal volume of 16 mL/breath and 4 cm H2O of CPAP, the relative iWOB 
reduction was over 85% both for the new system with and without prongs when compared to 
T-piece. Increasing CPAP level led to increased iWOB for the T-piece systems but decreased 
iWOB for the new system. 
In the clinical feasibility trial, a total of 39 infants were randomized, of whom 36 needed 
support. 12 infants received support with T-piece, 12 infants the new system with facemask 
and 12 infants the new system with prongs. There was a statistically significant imbalance 
between the groups with respect to gestational age. All patients received the randomized 
system until at least 10 min of age except for 1 patient who was intubated. There were no 
statistically significant differences in DR outcomes between the groups. In NICU, more 
infants treated with the new system and prongs received surfactant in the first 72 hours. 
However, the infants in this group were also statistically more immature with a median GA of 
30w+5d compared to 33w+0d for T-piece and 32w+2d in the other new system group. Two 
infants, both w 27 GA, in the new system with prongs developed pneumothoraxes. In both 
cases, pneumothorax developed after intubation in NICU. There were no other patient safety 
issues detected, and no problems related to equipment or usage. 
5.2 PAPER II 
The disposable Medijet differed from the other variable flow devices when simulated airway 
flow was tested both through the prongs versus the driver port. The resistance was 
comparable feeding air from either side so the mechanism for pressure generation resembled 
more a continuous flow resistor system than a variable flow system. This was not seen the for 
the Infant Flow, Benveniste valve nor reusable Medijet with or without the clip. In the static 
tests with a prespecified CPAP level the Neopuff and the Medijet disposable generator had 
the highest resistance, the Infant flow and Benveniste the lowest and the reusable Medijet in 
the middle. The reusable Medijet showed lower resistance without the clip. The dynamic tests 
showed the same pattern as for resistance, with the highest iWOB for the disposable Medijet 
and Neopuff. Because the Neopuff system has an adjustable resistor valve, by increasing flow 
and loosening the valve, iWOB decreases and pressure stability increases at any given CPAP 
level. 
5.3 PAPER III 
The original Pumani system was designed without a bleed valve with the risk of rebreathing 
and carbon dioxide accumulation. A bleed valve was added after communication with our 
research group and the system tested in this paper was the revised Pumani system with a 
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bleed valve. We tested the bleed valve flow and even at low CPAP pressures the flow 
exceeded 1 l/min so the risk for rebreathing is minimal in this revised design. 
When tested for the effect of submersion the conventional bCPAP systems (the Diamedica 
and the Fisher and Paykel), CPAP was dependent mainly on submersion depth and fresh gas 
flow only had marginal effect. For the Pumani system, submersion depth had almost no effect 
on delivered pressure and was dependent on fresh gas flow instead. 
When tested for resistance, the Fisher and Paykel system had the lowest resistance and the 
Diamedica slightly higher. The Pumani system tubing had substantially higher resistance. 
The resistance was higher than the resistance of an uncut 3.5 mm endotracheal tube that was 
used for comparison. The Pumani tubing system contains multiple connections. 
Disconnecting parts decreased resistance measured after every connection. The resistance of 
the revised Pumani system tubing, without fresh gas flow or submersion, was higher than in 
both conventional bubble CPAP systems. The resistance was higher than an uncut size 3.5 
endotracheal tube. Disconnecting parts of the revised Pumani tubing reduced resistance. 
Submersion depth and fresh gas flow had now effect on the resistance of the Pumani system 
and the prongs used for the system also had high resistance. The Pumani system had the 
highest iWOB of the systems tested, including NeoPuff that was also measured for 
comparison as a true resistor system. 
In summary, the revised Pumani system had high resistance, high imposed work of breathing 
and submersion depth had almost no impact on pressure delivered which is the main CPAP 
mechanism of true bCPAP systems.  
5.4 PAPER IV 
A summary of screening, inclusion, randomization and treatment is found in Figure 4. The 
two groups were similar in respect to demographics and clinical characteristics. Exposure to 
antenatal steroids was high, with over 98% receiving at least one dose in both groups. Intra 
uterine growth retardation (25.0% vs 18.0%), multiple births (21.0% vs 18.9%) and general 
anesthesia during C-section (16.1% vs 7.8%) was more common in the new system group. 
Humidification, which was optional to centers if used in both groups, was 46.3% in the new 




Figure 4: Flow diagram of patients in the CORSAD study. 
 
The primary outcome was defined as intubation or death in the DR within the time frame of 
0-30 minutes. In the new system group 33.1% (41/124) of the infants were intubated or died 
in DR and 45.1% (55/122) in the T-piece group. The adjusted odds ratio was statistically 
significant after adjusting for stratification variables (adjusted OR= 0.53, [95% CI 0.30 to 
0.94], P= .03; adjusted RD = -14.6% [CI -26.5% to -2.6%]). One infant in the new system 
group was intubated at 45 minutes in the DR but did not meet the primary outcome criteria 
because this was after the prespecified time frame of 0-30 minutes. One additional infant in 
the new system group was born with malformations that were not known prior to delivery, 
got treatment limitations at 2 minutes of age and died at 66 minutes of age. 
None of the secondary outcomes were statistically significant after correction for multiple 
comparisons. There were a total of 4 deaths in the DR, 3 in the new system group and 1 in the 
T-piece group. 12 infants died within 72 hours in the NICU, 6 in each group. Allocated 
treatment violations, reports of AE and technical issues more frequent in the new system 
group. Interface was changed in 9 infants from prongs to facemask in the new system group. 
The DMC did not find that deaths or serious averts events (SAE) were connected to devices 
used nor the trial protocol. In Figure 5 important safety secondary outcomes are shown as 
odds ratio. 




Assessed for eligibility 441 mothers
Excluded (n=216) 
   Not eligible or not approached (n=8) 
   Declined to participate (n=27) 
   Informed, consent not obtained (n=39) 
   Consent but not randomised (n=140) 
   Exclusion criteria (n=3) 
   Did not give birth (n=103), not reported (n=13) 
   Logistics and no investigator (n=16) 
   Transfer (n=5) 
   Duplicates (n=2)
Admitted n=121 
Analysed intention to treat n=121 
Lost to follow-up n=0 
Deaths in NICU n=6 
Alive at three days of age n=115
Allocated to rPAP n=127 
Stillborn n=3  
Analysed as intention to treat n=124 
Did not receive allocated treatment n=5 
Deaths in DR n=3
Admitted n=121 
Analysed intention to treat n=121 
Lost to follow-up n=0 
Deaths in NICU n=6 
Alive at three days of age n=115
Allocated to T-piece n=123 
Stillborn n=1 
Analysed as intention to treat n=122 
Did not receive allocated treatment n=2 
Deaths in DR n=1
DR Allocation
72 h NICU Follow-





Figure 5: Secondary NICU outcomes of the CORSAD study. OR below 1.0 favors the new system. 





Since the first CPAP for use in newborns was designed and described by Gregory in the 
1970’, numerous devices and techniques have been developed to give non-invasive 
respiratory support to newborn term and preterm infants. It became clear early on that a 
simple resistor system as the Gregory CPAP would be hard to breathe through and a simple 
but brilliant solution emerged. It involved changing from a resistor clamp to submersing the 
exhaustion tube in water to generate the CPAP pressure. Since then, the bubble CPAP design 
has prevailed and is still a very good alternative to more modern and expensive CPAP 
devices that have been developed. Research on new devices used for neonatal non-invasive 
respiratory support is suboptimal, and in some cases lacking entirely. The responsibility of 
manufacturers is unclear and the regulatory body is not up to standard compared to for 
example new pharmaceuticals. 
This thesis focuses on evaluating existing CPAP devices and technique and also comparing a 
newly developed device for resuscitation to the standard device recommended in 
International guidelines. We have been involved in the design of the new device, performed a 
pilot study using the device and completed a multicenter randomized controlled trial with 
focus on important clinical outcomes for newborn extremely preterm infants. 
When devices are developed and marketed, it is important that the devices actually perform in 
the way they are intended to, and that they are used correctly. The T-piece device is a 
resuscitator, labelled as such and is not marketed as a CPAP device and is designed to use 
with a facemask. It is pressure unstable and has high imposed work of breathing.34 It is not 
meant as CPAP for intermediate nor long term respiratory support. Therefore, attention to 
pressure stability or iWOB has not been in focus in its design. However, the T-piece is widely 
used for longer periods of time than it takes to stabilize an infant, as during transport from the 
DR to the NICU and also in rural areas that do not have standard CPAP devices on site.57 
This prolonged respiratory support with a T-piece is of unsure risks and benefits. 
In papers II and III we have evaluated the design and performance of two commercially 
available CPAP devices. The Medijet and the Pumani CPAP devices are described and 
marketed in a certain way. The original Medijet was built on the Benveniste valve 
technique.58 One of the concerns with the Benveniste valve was the noise because of its open 
design. To make the Medijet device more attractive and modern, modification were 
successively made over the years to minimize noise and make the device disposable. This 
redesign however had costs when it comes to performance. The disposable Medijet is said to 
be a variable flow device. We have shown, when tested in the lab, that it has almost none of 
the qualities that are the hallmark of variable flow devices. Pressure instability, high imposed 
work of breathing and mechanisms resembling classic resistor devices make it unlikely that 
the disposable Medijet is a variable flow CPAP device. It has never been proven in trials that 
pressure stability and iWOB is of clinical importance, nevertheless it is still important for 
manufacturers to describe their product in the right way so the users can tailor their treatment 
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accordingly. For example, higher CPAP pressure leads to higher imposed work of breathing 
when using the Medijet but not for the Infant Flow in. For some infants this could potentially 
be important. 
The revised Pumani tested in paper III was described as a bubble CPAP device.59 The 
traditional view on the mechanism of bCPAP is that the submersion level reflects the pressure 
delivered to the patient. When we tested the Pumani, the submersion level had no correlation 
to the pressure delivered.60 Pressure was mainly created by the resistance of the tubing 
system. Placing the submersion bottle in the circuit ahead of the patient interface and a 
bleeding valve makes it understandable that the submersion level would have minimal 
impact. When the Pumani was presented in a conference in 2015, there was no bleeding valve 
and the tubing had a blind end after the patient interface. After reaching out to the researcher 
and creators of the system and pointing out the risk for rebreathing, the bleeding valve was 
added. At the same time, we pointed out that the tubing of the system had high resistance and 
that the submersion level could not be used to set delivered pressure. After the publication of 
our paper and measurements in their own lab, the RICE 360 group changed the design of the 
Pumani again and it now has the original bubble CPAP design with the submersion bottle 
placed after the patient interface.61  
In paper I and IV we evaluate a new system that is now marketed and sold under the name 
rPAP. This system was designed with pressure stability and low iWOB in focus.54 
Drevhammar et al noticed in an in vitro simulation that the traditional T-piece was pressure 
unstable and had high iWOB in comparison with traditional CPAP devices such as Infant 
Flow and bubble CPAP.34 The interface for the T-piece is a face mask, the same as for other 
resuscitation devices such as the self-inflating ambu bag. Capasso et al had shown in a 
clinical study that a nasal interface was an alternative to a face mask.62 In that study fewer 
intubations were observed when using nasal prongs compared to using face mask for 
resuscitating newborn infants. The ILCOR guidelines included the alternative of using a nasal 
interface instead of facemask in their guidelines already in 2010 and successive 
guidelines.44,55,63 Designing and testing a device that is pressure stable, with low imposed 
work of breathing and a nasal interface was therefore an attractive next step in our research. 
In paper I, the in vitro tests of the new rPAP design clearly showed that there was a 
substantial difference in iWOB between two different brands of T-piece systems and the new 
system. It also showed that whilst the iWOB increased for the T-piece with increased CPAP 
level the iWOB decreased for the new system. The small feasibility trial showed that the new 
system was easy to use and did not reveal any safety issues when using the device, neither 
with face mask or prongs. The groups were imbalanced with regards to GA but this could be 
expected due to randomization, sites and a small sample size.  
In paper 4 we were able to show that using the new system with nasal prongs decreased DR 
intubation of extremely preterm infants compared with using a traditional T-piece. Using the 
primary outcome of DR intubation or death instead of the traditional outcome of BPD or 
death in similar trials40-43,64 is debatable. However, the BPD diagnosis criteria have been 
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criticized in recent years and at least 2 new definitions are currently discussed in different 
forums.65,66 The outcome of DR intubations for extremely preterm infants has been graded as 
important in the newest update of the ILCOR guidelines in 2020.44 Creating a window of 
opportunity for avoiding intubation and mechanical ventilation and giving surfactant using 
minimally invasive techniques or non-invasively, is worth pursuing. 
Reassuringly, none of the secondary outcomes were significant or showed a trend towards 
poor safety issues or worse clinical outcomes for the new system in the first 72 hours. 
As mentioned earlier, despite evidence from the adult populations67, imposed work of 
breathing has not been shown to have clinical significance in neonatal setting. This is mainly 
due to insufficient research in the area, with no control over important factors such as leakage 
and equal experience off trial staff using different systems. It has repeatedly been shown that 
the resistance, size and iWOB of different nasal interfaces and prongs differ and that this may 
have clinical importance.12,26,28,30 On the other hand, hard evidence for or against this view is 
not readily available. Based on both our own research and other groups research, I believe 
that it is wrong to assume that all modern CPAP generators and tubing systems have minimal 
resistance and minimal imposed work of breathing. Making such assumption could, in a 
worst-case scenario lead to harm for newborn patients. 
Delivering non-invasive long-term respiratory support via the nose to infants, has been 
standard with CPAP, high flow and low flow nasal cannula and has been so for a long time in 
the NICU setting. Infants are “preferred nasal breathers” 68and therefore ,the optimal and least 
invasive route giving respiratory support is through the nose. However, traditionally, non-
invasive respiratory support in the DR has been delivered via facemask with the possibility of 
giving PPV. Using a facemask for stabilization can be challenging. Mask leakage and airway 
obstruction are common when using a face mask, often undetected by the user.69-72 A few 
trials in the past 20 years, have investigated whether nasal interfaces are better suited to 
deliver this initial respiratory support after birth.62,73-75 Recently, 2 systematic reviews have 
been published on the subject, to see which is more effective and favorable, nasal interfaces 
or the face mask. Although both conclude that nasal interfaces may be more favorable, both 
were inconclusive.76,77 In an editorial in Resuscitation, concerns about using the facemask as 
interface is raised and pointed out that more trials comparing facemask and nasal interfaces 
are needed.78 
Caring for extremely premature babies is very expensive but the number of patients is 
limited. There are very few drugs that are tested and approved for use on these patients. The 
same applies to medical technology. This is because it is difficult to conduct studies in this 
patient group, and because the potential market is small. It is an ethical dilemma that research 
on premature babies is relatively neglected, despite its importance from a patient, relative and 
care perspective. The evidence-based care that we seek is difficult to achieve in practice. 
However, it is our duty as physicians and researcher to test and evaluate newly developed 
devices and, preferably, without the direct involvement of the Med Tech industry. Seeking 
consent with parents is important, however recently it has been pointed out that the use of 
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waiver of consent and retrospective consent might be crucial moving forward in DR 
resuscitation trials and generate reliable evidence for the future.79 
 
6.1 LIMITATIONS 
The in vitro tests used in paper I, II and III are limited by the artificial nature of such models. 
In our model there was no leakage, a symmetrical sinusoidal flow pattern (i:e 1:1) was used 
and the model was non-compliant. In vitro tests like these can be criticized for not reflecting 
how devices are used, how the total work of breathing may change, and whether the results 
are clinically relevant. Simulations may underestimate iWOB for systems which are pressure 
unstable with large pressure swings because of tube compliance and gas compression, which 
will lead to a reduction in delivered volumes. Correcting for this artifact is complicated and 
was not attempted in our measurements. Large differences in iWOB between devices were 
seen and this was regardless of the specified tidal volume. It is therefore plausible that the 
difference will be present if other profiles than the tested tidal volumes are used. Despite the 
limitations of modelling, it is still useful to describe the true quality and mechanism of a 
devices, and the findings can be easily reproduced by other research groups. 
In the clinical feasibility trial (paper I), the absence of stratification and the small number of 
patients resulted in an imbalance between the treatment groups. The group treated with the 
new system and prongs had significantly lower gestational ages. This must be considered 
when interpreting the results of the trial. Furthermore, the inability to perform a blinded trial 
always leads to the risk of bias, especially with only a few investigators involved in the trial. 
The small number of patients also makes it hard to draw definite conclusions about the safety 
and treatment effect of the new system.  
The RCT in paper IV has several limitations. First, the trial was not blinded which leaves a 
potential for selection bias. This is a universal problem for all intervention trials of newborn 
infants in the DR. Despite clinical management guidelines and criteria for intubations this 
risk for bias can never be excluded. In an attempt to reveal possible bias secondary outcomes 
were included, such as time to intubation after initial stabilization. Secondly, only including 
infants to mothers that gave antenatal consent is also a risk factor for bias, because it excludes 
the sickest infants born (for example) after admission with emergency c/sections due to either 
mother or infant indications. These infants are often not subjected to the beneficial effect of 






Devices used for non-invasive neonatal respiratory support are diverse and vary in their 
construction as well as function. Resistance, pressure stability, interfaces and imposed work 
of breathing differ markedly. However, these aspects are still of uncertain clinical 
importance. In the 2010 ILCOR guidelines the following questions were asked: “What is the 
appropriate interface to effectively ventilate infants…? What is the optimal device for 
delivering PEEP and CPAP?”. Eleven years later, I believe that the findings presented in this 
thesis have brought us one step closer in answering these questions. 
• A new device (rPAP), was shown in a mechanical lung model to be pressure stable 
and have low imposed work of breathing compared to the T-piece. The feasibility trial 
comparing these devices revealed no safety issues when stabilizing preterm infants 
with the new device. 
 
• The main mechanism of CPAP generation for the disposable Medijet generator is 
resistance. The Medijet systems shows increasing resistance to breathing with each 
design generation. Our results suggest that the disposable Medijet should be used 
cautiously in patients for whom low-resistance and pressure-stable CPAP is believed 
to be clinically important. 
 
• The revised Pumani system had high resistance, high imposed work of breathing and 
submersion depth had almost no impact on the delivered pressure which is the main 
CPAP generating mechanism of true bubble CPAP systems. After the publication of 
our results the system has been revised again and has now the conventional bubble 
CPAP design. This paper highlights the continued need for critical review and testing 
of new CPAP designs with uncertain clinical implications before they are released on 
the commercial market. 
 
• Using a new system (rPAP), which has low imposed work of breathing and nasal 
prongs as interface, decreased delivery room intubations in extremely preterm infants 
compared with using the T-piece and face mask. This creates a window of 






8 POINTS OF PERSPECTIVE 
We have continued evaluating devices and interfaces.80-84 This is of great importance 
especially when regulations and notifying body for medical devices are sub-standard. 
Understanding the mechanism of how devices work and measuring their performance is of 
value. Performing clinical trials to test the importance of resistance, leakage and imposed 
work of breathing is urgent, especially for our smallest infants, for whom the margins 
between life, death and serious morbidity are minimal. We have several trials completed and 
underway looking at devices and their qualities.  
When we started our journey 10 years ago with a new device, intended to stabilize the 
preterm infant in a gentle and non-aggressive way we were swimming against the stream. 
Sustained inflation with high inflating pressure and an aggressive approach in the DR was 
gaining momentum and thought to be the way forward to lower morbidity and mortality in 
the smallest infants. Since then, studies have showed that this aggressive approach can have 
serious consequences and even increase mortality. The new approach with early CPAP, 
avoiding PPV if possible and physiological cord clamping is gaining popularity. The new 
device we have designed and tested is optimal for such support. New DR studies should focus 
on a bundle of non-aggressive stabilizing methods and giving our smallest and most 





9 SUMMARY IN SWEDISH 
 
 
Att undvika mekanisk ventilation i neonatalperioden kan minska sjuklighet och dödlighet hos 
förtidigt födda barn. Att istället använda icke-invasiv ventilation och CPAP har visat sig vara 
bra för att undvika intubation och mekanisk ventilation. CPAP användning kan förhindra 
utveckling av kronisk lungsjukdom hos mycket förtidigt födda barn. CPAP som 
andningshjälp för nyfödda barn började användas tidigt på 70-talet. Sedan dess har flera olika 
CPAP system utvecklats. Några av systemen är utvecklade för att ge långvarigt andningsstöd 
medan andra är utvecklade för initialt stöd, med möjlighet att ge övertrycksventilation (PPV) 
om det behövs. Vissa CPAP system är dyra och komplicerade med flera tilläggsfunktioner 
medan andra är billiga, med enkla mekanismer för att generera tryck och är användarvänliga. 
Målet för CPAP-behandling är att ge spädbarn kontinuerligt luftvägstryck för att minimera 
andningsarbetet och förbättra gasutbytet. Men är alla CPAP system likadana? Levererar alla 
CPAP system stabilt luftvägstryck som hjälper spädbarn med deras andningsarbete? 
Avhandlingens övergripande syfte var att utvärdera befintliga och nyutvecklade system för 
icke-invasivt andningsstöd som används hos nyfödda i förlossningsrummet och på 
neonatalavdelningar. Tryckstabilitet, extra andningsarbete samt patientgränssnitt var i särskilt 
fokus. 
Syftet med arbete I var att undersöka egenskaper och prestanda för ett nytt system (rPAP) i 
mekanisk lungmodell. Dessutom att göra en klinisk pilotstudie där det nya systemet 
jämfördes med traditionellt T-stycke, vid initial stabilisering av förtidigt födda barn. Det nya 
systemet visade sig vara tryckstabilare och ha lågt påfört andningsarbete jämfört med T-
stycket. Pilotstudien visade inga säkerhetsproblem i samband med användning av det nya 
systemet.  
Syftet med arbete II var att undersöka in vitro-prestanda för olika generationer av Medijet 
CPAP systemen och jämföra dessa med andra CPAP-system. Huvudmekanismen för CPAP-
generation för Medijet-engångsgeneratorn visade sig vara motstånd. Medijet-systemen visar 
successivt ökande andningsmotstånd för varje designändring. Våra resultat tyder på att 
Medijet engångsgeneratorn bör användas med försiktighet till patienter där låg resistens och 
tryckstabilitet av andningshjälpen tycks vara av vikt. 
Syftet med arbete III var att jämföra det reviderade Pumani CPAP-systemet med två 
traditionella bubbel CPAP-system, med fokus på in vitro-prestanda och säkerhet. Det 
reviderade Pumani-systemet hade högt motstånd och högt pålagt andningsarbete. 
Nedsänkningsdjupet som är den huvudsakliga CPAP-genereringsmekanismen för sanna 
bubbel CPAP-system hade minimal påverkan på levererat tryck för Pumani systemet. 
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Syftet med arbete IV var att utvärdera om användning av det nya systemet (rPAP) med 
näsprångar som gränssnitt, skulle kunna minska behovet av intubation av mycket förtidigt 
födda barn direkt efter förlossning. Det traditionella T-stycket med ansiktsmask användes 
som jämförelse. Den randomiserade kontrollerade CORSAD-studien visade att användning 
av det nya systemet minskade intubationer i förlossningsrummet hos mycket förtidigt födda 
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